Status:
RECRUITING
The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
Lead Sponsor:
Queen Mary University of London
Collaborating Sponsors:
Barts & The London NHS Trust
Homerton University Hospital
Conditions:
Parkinson's Disease and Parkinsonism
Progressive Supranuclear Palsy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioura...
Detailed Description
Parkinson's disease (PD) may be the fastest growing neurodegenerative disease in the world (Bloem et al., 2021). Pathologically, it is characterised by the loss of the dopaminergic neurons within the ...
Eligibility Criteria
Inclusion
- Adults over 18 years old
- Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)
- willing to participate and written consent provided after read the participant information sheet.
Exclusion
- Individuals with:
- other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait
- metabolic or autoimmune disorders affecting movement, balance and gait
- acute orthopaedic disorders influencing balance control and gait
- audiovestibular disorders including severe hearing loss
- visual disturbances, poor eyesight
- not able to provide written consent form to participate
- clinical diagnosis of cognitive impairment including dementia or Alzheimer's.
- Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)
- Technical contraindications related to CUE1 device:
- implanted metallic or electronic devices usage
- hypersensitivity to vibrotactile stimulation
- skin conditions and/or open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.
Key Trial Info
Start Date :
March 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06174948
Start Date
March 25 2024
End Date
March 31 2025
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary University of London
London, United Kingdom, EC1M 6BQ